VTRS Viatris Inc. Common Stock

XNAS 20.49 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

VTRS $20.49 —
Key stats
$20.49
52-Week Range
$9.98 – $20.52
YTD
+64.47%
IV Rank (30D)
42.54
Straddle Price
$1.68
P/C Vol Ratio
0.34
Market Cap
$22.8B
Open
$20.11
Day Range
$19.90 – $20.52
Volume
8,093,665
Prev Close
$19.91
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY0.90
Cost of Equity (CAPM)9.39% (VRP-adj)
WACC7.94%
Volatility Risk Premium+8.5pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-0.3%
DCF Horizon5 years explicit + fade
Free Cash Flow (TTM)$2.0B
Return on Equity (TTM)-2.9%
Book / Price59.8% — banking bias active (P/B is primary)
Gross Margin (TTM)35.3%
FCF Margin (TTM)13.3%
Debt / Equity0.85
Quality Score1/6 — cyclical/struggling (5y DCF)
Market-Implied Growth-0.2% (reverse-DCF on current price)
SMA 50$17.70 (Market Anchor value)
SMA 20 / Bollinger Mid$18.53
Bollinger Width / SMA2013.6% (drives anchor stability)
Net Debt$9.8B
Market Cap$23B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
40%
20-Day Fair Value
≈ by Dec 8, 2026
$20.47
α -0.1% rank 70%
conviction
9%
40-Day Fair Value
≈ by Jan 6, 2027
$20.63
α +0.7% rank 70%
conviction
26%
60-Day Fair Value
≈ by Feb 4, 2027
$20.20
α -1.5% rank 70%
conviction
40%
MethodImplied PriceWeightDetail
DCF $19.79 22%
DDM (Gordon) $6.19 18%
Peer P/E n/a 0% median 42.2× · 3 peers
Peer EV/EBITDA $45.37 7% median 21.2× · 3 peers
Peer P/B $45.99 9% median 3.9× · 3 peers
Peer P/S $52.31 9% median 4.1× · 3 peers
Market Anchor (SMA50) $17.70 36% stability 82% (BB-width)
Options Expected (B-L 30d) $20.21 0% 6 strikes · skew +0.11
As of 2026-11-09 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$22.8B
Employees
30,000
List Date
1973-02-23
CIK
0001792044
Last Earnings
Nov 5 before open · −1.3% vs ±8.3% expected
Next Earnings
~Feb 25, 2027 (estimated)
Headquarters
Canonsburg, PA
Homepage
https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-8.36%5.35%6.85%3.34%-9.18%5.06%0.51%
Feb-14.88%-26.94%-7.01%4.21%-16.39%9.14%-8.65%
Mar-5.10%7.19%-14.94%-5.16%-6.65%-13.95%-6.43%
Apr-4.32%-4.53%-2.91%-3.10%-2.09%9.61%-1.22%
May12.89%20.18%-2.24%-8.86%3.78%8.11%5.64%
Jun-6.36%-13.26%8.71%0.47%2.76%0.44%-1.21%
Jul-4.61%-9.52%6.47%13.88%-4.79%9.00%1.74%
Aug2.81%-1.14%5.19%1.00%19.75%-6.35%3.54%
Sep-7.13%-10.97%-8.62%-2.35%-6.25%6.55%-4.79%
Oct-1.84%16.17%-11.44%0.96%2.68%9.02%2.59%
Nov-10.93%7.61%2.91%12.65%1.52%9.88%*3.94%
Dec11.91%-0.98%15.58%-5.68%16.36%--7.44%
Total-33.28%-19.06%-5.99%9.19%-4.04%53.01%-0.03%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $18.68
SMA 50: $17.78
SMA 200: $16.09
Current: $20.50
EMA 12: $19.16
EMA 26: $18.60
MACD: 0.5631 | Signal: 0.1289
BULLISH
ADX (14): 27.97
TREND
+DI: 34.11
−DI: 10.55

Momentum Oscillators

RSI (14): 72.13
OVERBOUGHT
Stoch %K: 83.18
Stoch %D: 76.20
Williams %R: -0.94

Volume & Volatility

BB Upper: $20.12
BB Lower: $17.24
OVERBOUGHT
OBV: 321,873,607
Vol SMA 20: 8,985,632
Vol ROC: 32.46%
ATR: $0.58
True Range: $0.62
HV 20: 34.4%
HV 30: 30.5%
HV 60: 25.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before VTRS’s Nov 5 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall assessment: NEUTRAL with confidence level (6/10)

Key drivers:

  • Positive news sentiment from recent headlines
  • Moderate volatility, following market trends
  • Bullish momentum signals from MACD and ADX indicators

Primary risks:

  • Negative earnings surprise or guidance change
  • Regulatory setbacks in the pharmaceutical industry
  • High implied volatility affecting options trading

Investment thesis: VTRS presents a moderate-risk opportunity with potential for long-term growth. The stock is supported by positive news sentiment, trending upward, and exhibiting bullish momentum signals.

Recent news sentiment impact: Positive news headlines have contributed to the stock's recent price appreciation, indicating a supportive environment.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BULLISH, Long-term (3-12 months): BEARISH

Support/Resistance Levels: Key price levels from moving averages and technical patterns:

  • SMA 20: $16.16
  • SMA 50: $15.44
  • SMA 200: $12.85
  • EMA 12: $16.11
  • EMA 26: $16.00

Momentum Signals:

  • RSI (14): 57.47 (neutral)
  • MACD: 0.12 / Signal: -0.04 / Histogram: 0.15 (bullish)
  • ADX (14): 19.03 — regime: range

Volume Analysis: Volume trends and institutional interest signals:

  • Volume SMA 20: 9679711.65
  • On-Balance Volume (OBV): 300272830.98
  • Volume Rate of Change: -63.19%

News & Sentiment Analysis

Recent Headlines Summary: Key themes from last 10 news articles: Positive sentiment driven by pharmaceutical industry research and announcements.

Sentiment Assessment: Aggregate news sentiment: POSITIVE (7/10)

Catalyst Identification: Upcoming events, earnings, product launches:

  • No recent earnings data available
  • Product launch or partnership announcements could drive future price appreciation

Market Narrative: News aligns with technical signals, supporting the stock's upward trend.

Risk & Volatility Assessment

Beta Interpretation: Risk relative to market: Beta 0.89 (moderate volatility)

Volatility Regime: Current vs historical volatility levels:

  • Average True Range (ATR): $0.44
  • Historical Volatility: HV20 32.0% / HV30 38.5% / HV60 33.4%

Options Market Signals:

  • IV Rank: 62.4% (Medium)
  • Current IV: 113.6%
  • Expected Move: $1.35 (35 DTE), 7-DTE: $0.65

Market Context & Positioning

Sector Performance: Relative strength vs sector/market:

  • Moderate performance within the pharmaceutical industry sector

Institutional Activity: Volume patterns suggesting institutional interest signals:

  • Institutional ownership: Not disclosed
  • Insider trading activity: Not disclosed

Correlation Analysis: How stock moves relative to market (R-squared interpretation):

  • R-squared value not available for this analysis period

Key Levels & Action Items

Critical Price Levels: Support/resistance to monitor:

  • SMA 20: $16.16
  • SMA 50: $15.44
  • SMA 200: $12.85

Breakout/Breakdown Levels: Technical levels that could trigger significant moves:

  • Upper Bollinger Band: $16.79
  • Lower Bollinger Band: $15.54

Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:

  • No recent earnings data available
  • Product launch or partnership announcements could drive future price appreciation

Risk Management: Stop-loss levels and position sizing considerations:

  • Consider setting a stop-loss at $16.00 to limit potential losses
  • Position size should be adjusted based on individual risk tolerance and market conditions
Generated
News
All VTRS news →
Showing 1–10 of 15
Page 1 of 2
Earnings History
16 of 23 under expected move
Avg Expected Move
7.74%
Avg Actual Move
7.17%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-22 Pre-Market 6.75% 14.88% 2.20x Exceeded
2021-05-10 Pre-Market 4.62% 6.82% 1.48x Exceeded
2021-08-09 Pre-Market 5.61% 5.96% 1.06x Exceeded
2022-02-28 Pre-Market 8.94% 24.28% 2.72x Exceeded
2022-05-09 Pre-Market 8.74% 5.33% 0.61x Within
2022-08-08 Pre-Market 8.12% 3.70% 0.46x Within
2022-11-07 Pre-Market 8.14% 13.09% 1.61x Exceeded
2023-02-27 Pre-Market 6.78% 2.69% 0.40x Within
2023-05-08 Pre-Market 8.62% 5.82% 0.68x Within
2023-08-07 Pre-Market 6.61% 3.87% 0.59x Within
2023-11-07 Pre-Market 8.47% 0.87% 0.10x Within
2024-02-28 Pre-Market 7.56% 7.11% 0.94x Within
2024-05-09 Pre-Market 6.77% 5.00% 0.74x Within
2024-08-08 After-Close 5.17% 2.64% 0.51x Within
2024-11-07 Pre-Market 6.89% 13.52% 1.96x Exceeded
2025-02-27 Pre-Market 9.12% 15.21% 1.67x Exceeded
2025-05-08 After-Close 5.50% 3.52% 0.64x Within
2025-08-07 Pre-Market 10.29% 7.31% 0.71x Within
2025-11-06 After-Close 8.65% 0.10% 0.01x Within
2026-02-26 Pre-Market 9.64% 5.16% 0.54x Within
2026-05-07 Pre-Market 10.03% 9.03% 0.90x Within
2026-08-06 Pre-Market 8.78% 7.71% 0.88x Within
2026-11-05 Pre-Market 8.32% 1.30% 0.16x Within

Earnings calendar: this week’s reports with expected vs actual moves →

VTRS Options Activity & IV Rank

VTRS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 30.9%
7-DTE IV: 35.4%
Expected Move: $1.68
7-DTE Move: $1.15
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 2,631
Put Volume: 897
P/C Volume: 0.341
BULLISH
Call OI: 95,699
Put OI: 25,269
P/C OI: 0.264
Total OI: 120,968

ATM Options Pricing

ATM Call: $1.05
ATM Put: $0.62
Call %: 5.1%
Put %: 3.0%

Chain Summary

Chain Volume: 3,528
Chain OI: 120,968
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
99%
vs own history
GEX tilt
+0.80
OI-weighted, today
Vanna tilt
-0.48
δ-sensitivity to IV
Charm tilt
+0.15
δ-decay vs time
Vanna tilt -0.48: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 24 ATM contracts, 24k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)13.1LowNov 9
IV Rank (30 DTE)42.5MediumNov 9
Straddle Price (30 DTE)$1.68Nov 9
Beta Analysis

Risk Metrics

Beta: 0.6480
Alpha: 68.03%
Correlation: 0.2756
R-Squared: 7.6%
Stock Volatility: 32.4%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own VTRS
6 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Glenview Capital Hedge fund
Larry Robbins
$156.9M
3.13%
#11 of 42+8.7%13F
Bridgewater Associates Hedge fund
Ray Dalio
$27.0M
0.11%
#154 of 997+134.0%13F
Point72 Hedge fund
Steve Cohen
$8.9M
0.01%
#791 of 1945-68.3%13F
Citadel Hedge fund
Ken Griffin
$8.0M
0.00%
#1756 of 6285-87.4%13F
Millennium Management Hedge fund
Izzy Englander
$5.0M
0.00%
#2056 of 3716-88.6%13F
Rockefeller Capital Management Family office
Rockefeller family
$852K
0.00%
#1806 of 4729-10.4%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

VTRS Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 1,160,933,000 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

1,057 filers1,043,061,897 shares$16.85B value89.85% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 96,662,102 $1.53B 9.11% 8.33% 2026-06-30
2 BlackRock, Inc. Custodian 86,019,468 $1.37B 8.11% 7.41% 2026-06-30
3 Vanguard Capital Management LLC 76,046,939 $1.21B 7.17% 6.55% 2026-06-30
4 Davis Selected Advisers 75,232,254 $1.19B 7.09% 6.48% 2026-06-30
5 T. Rowe Price Associates, Inc. 68,214,436 $1.08B 6.43% 5.88% 2026-06-30
6 Vanguard Portfolio Management LLC 54,282,080 $862.00M 5.11% 4.68% 2026-06-30
7 State Street Corp 53,069,461 $842.74M 5.00% 4.57% 2026-06-30
8 Geode Capital Management, LLC Custodian 33,044,631 $584.56M 3.47% 2.85% 2026-09-30
9 Rubric Capital Management LP 34,168,743 $542.60M 3.22% 2.94% 2026-06-30
10 Invesco Ltd. Custodian 20,771,275 $329.85M 1.96% 1.79% 2026-06-30
11 DEERFIELD MANAGEMENT COMPANY, L.P. 20,206,170 $320.87M 1.90% 1.74% 2026-06-30
12 Dimensional Fund Advisors LP Custodian 17,201,193 $304.85M 1.81% 1.48% 2026-09-30
13 Ameriprise Financial, Inc. Custodian 18,815,747 $298.80M 1.77% 1.62% 2026-06-30
14 Morgan Stanley Custodian 15,128,899 $240.25M 1.43% 1.30% 2026-06-30
15 Bank of New York Mellon Corp Custodian 12,573,219 $222.80M 1.32% 1.08% 2026-09-30
16 Charles Schwab Investment Management, Inc. 13,567,342 $215.45M 1.28% 1.17% 2026-06-30
17 Goldman Sachs Group Inc Custodian 13,564,872 $215.41M 1.28% 1.17% 2026-06-30
18 Assenagon Asset Management S.A. 10,533,840 $186.66M 1.11% 0.91% 2026-09-30
19 Northern Trust Corp Custodian 10,038,691 $159.41M 0.95% 0.86% 2026-06-30
20 GLENVIEW CAPITAL MANAGEMENT, LLC 9,877,409 $156.85M 0.93% 0.85% 2026-06-30
21 LSV ASSET MANAGEMENT 8,387,114 $148.62M 0.88% 0.72% 2026-09-30
22 Arrowstreet Capital, Limited Partnership 8,371,218 $132.93M 0.79% 0.72% 2026-06-30
23 Callodine Capital Management, LP 8,000,742 $127.05M 0.75% 0.69% 2026-06-30
24 JPMorgan Chase & Co Custodian 7,322,267 $119.69M 0.71% 0.63% 2026-06-30
25 Bank of America Corp Custodian 7,356,708 $116.82M 0.69% 0.63% 2026-06-30
22 filers$141.76M notional
# Filer Notional Value % of Total Period
1 Nantahala Capital Management, LLC $79.40M 56.01% 2026-06-30
2 Susquehanna International Group, LLP Custodian $17.89M 12.62% 2026-06-30
3 Citadel Advisors LLC Custodian $10.50M 7.40% 2026-06-30
4 Converium Capital Inc. $5.24M 3.70% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $4.59M 3.24% 2026-06-30
6 Simplex Trading, LLC Custodian $4.17M 2.94% 2026-09-30
7 Walleye Capital LLC $4.12M 2.90% 2026-06-30
8 IMC-Chicago, LLC Custodian $3.47M 2.45% 2026-09-30
9 Squarepoint Ops LLC $2.54M 1.79% 2026-06-30
10 UBS Group AG Custodian $2.44M 1.72% 2026-06-30
11 Jane Street Group, LLC Custodian $1.85M 1.30% 2026-06-30
12 Caption Management, LLC $1.70M 1.20% 2026-06-30
13 Point72 Asset Management, L.P. $944.86K 0.67% 2026-06-30
14 CSS LLC/IL $605.03K 0.43% 2026-06-30
15 Parallax Volatility Advisers, L.P. $476.40K 0.34% 2026-06-30
16 PEAK6 LLC $476.40K 0.34% 2026-06-30
17 Two Sigma Investments, LP Custodian $341.42K 0.24% 2026-06-30
18 CAPITAL FUND MANAGEMENT S.A. $312.84K 0.22% 2026-06-30
19 TUDOR INVESTMENT CORP ET AL $285.84K 0.20% 2026-06-30
20 Wells Fargo & Company Custodian $268.37K 0.19% 2026-06-30
21 Walleye Trading LLC $111.16K 0.08% 2026-06-30
22 Marshall Wace, LLP Custodian $34.94K 0.02% 2026-06-30
16 filers$79.08M notional
# Filer Notional Value % of Total Period
1 MOORE CAPITAL MANAGEMENT, LP $21.13M 26.71% 2026-06-30
2 Caption Management, LLC $19.85M 25.10% 2026-06-30
3 Susquehanna International Group, LLP Custodian $11.51M 14.55% 2026-06-30
4 Jane Street Group, LLC Custodian $6.34M 8.02% 2026-06-30
5 Walleye Capital LLC $4.53M 5.73% 2026-06-30
6 Citadel Advisors LLC Custodian $3.84M 4.86% 2026-06-30
7 Squarepoint Ops LLC $3.03M 3.83% 2026-06-30
8 Walleye Trading LLC $2.43M 3.08% 2026-06-30
9 GROUP ONE TRADING LLC Custodian $1.72M 2.17% 2026-06-30
10 IMC-Chicago, LLC Custodian $1.68M 2.12% 2026-09-30
11 CAPSTONE INVESTMENT ADVISORS, LLC $1.35M 1.70% 2026-06-30
12 Simplex Trading, LLC Custodian $1.09M 1.38% 2026-09-30
13 UBS Group AG Custodian $292.19K 0.37% 2026-06-30
14 Two Sigma Investments, LP Custodian $179.44K 0.23% 2026-06-30
15 PEAK6 LLC $106.40K 0.13% 2026-06-30
16 Marshall Wace, LLP Custodian $11.12K 0.01% 2026-06-30

VTRS Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 David S Simmons Director Grant (A) +2,117 RSU — EDGAR
2026-10-02 Leo Frans Groothuis Director Grant (A) +2,469 RSU — EDGAR
2026-08-18 Andrew Enrietti See Remarks Mixed
Exer +26,133 · Tax −11,366
 +14,767 $16.23 -$184.5K EDGAR
2026-07-01 David S Simmons Director Grant (A) +2,362 RSU — EDGAR
2026-07-01 Leo Frans Groothuis Director Grant (A) +2,756 RSU — EDGAR
2026-06-26 Paul Campbell See Remarks Sell (S) −50,076 $16.17 -$809.8K EDGAR
2026-04-16 Corinne Le Goff Chief Commercial Officer Mixed
Exer +42,988 · Tax −19,067
 +23,921 $13.86 -$264.3K EDGAR
2026-03-24 Paul Campbell See Remarks Sell (S) −21,350 $13.28 -$283.5K EDGAR
2026-03-10 Elisha W Finney Director Exer (M) +24,835 — EDGAR
2026-03-10 W Don Cornwell Director Exer (M) +24,835 — EDGAR
2026-03-10 Frank A Damelio Director Exer (M) +26,031 — EDGAR
2026-03-10 Coelho Rogerio Vivaldi Director Exer (M) +24,835 — EDGAR
2026-03-10 Dillon JoEllen Lyons Director Exer (M) +24,835 — EDGAR
2026-03-10 James M Kilts Director Exer (M) +24,835 — EDGAR
2026-03-10 Leo Frans Groothuis Director Mixed
Exer +24,835 · Tax −1,305
 +23,530 $14.16 -$18.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

VTRS Insider Holdings

20 insiders · @ $20.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Scott Andrew Smith Chief Executive Officer 1,331,759 $27.29M $756.0K 8 2026-03-10
2 Rajiv Malik Director 612,895 $12.56M -$10.64M 15 2025-03-10
3 Paul Campbell See Remarks 316,530 $6.49M -$1.74M 15 2026-06-26
4 Andrew Enrietti See Remarks 233,880 $4.79M $0 4 2026-08-18
5 Melina E Higgins Director 218,873 $4.49M $0 11 2026-03-10
6 Mark W Parrish Director 164,055 $3.36M $0 11 2026-03-10
7 James M Kilts Director 160,082 $3.28M $489.7K 13 2026-03-10
8 Richard A Mark Director 116,145 $2.38M $0 11 2026-03-10
9 Harry Korman Director 113,164 $2.32M $61.3K 11 2025-03-10
10 W Don Cornwell Director 110,869 $2.27M $99.7K 13 2026-03-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

VTRS Board & Officers

As of SEC filings through Oct 2, 2026

Directors 13

Officers 5

Changes in the last 10 years (58)
May 1, 2026The company announced the departure of Theodora Mistras as Chief Financial Officer in an SEC filing
Feb 9, 2026Matthew Joseph Maletta became Chief Legal Officer
Feb 3, 2026The company announced the departure of Brian Roman as Chief Legal Officer in an SEC filing
Aug 15, 2025Andrew Enrietti became Chief Administrative and Transformation Officer
Aug 4, 2025David S Simmons became a director
May 5, 2025The company announced the departure of Rajiv Malik from the board in an SEC filing
May 5, 2025The company announced the departure of Harry Korman from the board in an SEC filing
May 5, 2025Michael Severino became a director
May 5, 2025Frank A Damelio became a director
Jun 3, 2024Coelho Rogerio Vivaldi became a director
May 28, 2024Brian Roman listed as Chief Legal Officer (previously Global General Counsel) in SEC filings
Apr 15, 2024Corinne Le Goff became Chief Commercial Officer
Mar 1, 2024Theodora Mistras became Chief Financial Officer
Dec 15, 2023Andrew Cuneo listed as President, JANZ (Japan, Australia and New Zealand) and Emerging Markets (previously President, JANZ (Japan, Australia and New Zealand)) in SEC filings
Dec 14, 2023The company announced the departure of Sanjeev Narula as Chief Financial Officer in an SEC filing
Oct 20, 2023The company announced the departure of Rajiv Malik as President in an SEC filing
Oct 20, 2023The company announced the departure of Anthony Mauro as President, Developed Markets in an SEC filing
May 19, 2023The company announced the departure of Robert J Coury from the board in an SEC filing
May 19, 2023The company announced the departure of Robert J Coury as Executive Chairman in an SEC filing
May 19, 2023Leo Frans Groothuis became a director
Not reported recently (5)
  • Andrew Cuneo · Last reported as President, JANZ (Japan, Australia and New Zealand) and Emerging Markets in an SEC filing dated Mar 5, 2024
  • Xiangyang (Sean) Ni · Last reported as President, Greater China in an SEC filing dated Mar 5, 2024
  • Meer Mohr Pauline van der · Last reported as a director in an SEC filing dated Mar 6, 2023
  • Menassie Taddese · Last reported as President, Emerging Markets in an SEC filing dated May 27, 2022
  • Neil F Dimick · Last reported as a director in an SEC filing dated Mar 23, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

VTRS Proposed Insider Sales (Form 144)

Latest: 2026-06-25
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-06-25 Paul Campbell Officer 50,076 $809.7K 2026-06-25 Merrill Lynch 10b5-1 EDGAR
2026-03-23 Paul Campbell Officer 21,350 $283.5K 2026-03-23 Merrill Lynch — EDGAR
2025-09-11 Le Goff Corinne Officer 7,032 $72.0K 2025-09-11 VIATRIS INC 10b5-1 EDGAR
2024-11-12 Campbell Paul Officer 26,925 $346.7K 2024-11-11 Merrill Lynch — EDGAR
2024-08-20 Malik Rajiv Director 600,000 $7.08M 2024-08-20 Charles Schwab Corporation — EDGAR
2024-06-13 Malik Rajiv Affiliate 350,000 $3.65M 2024-06-13 Charles Schwab Corporation — EDGAR
2024-05-28 Roman Brian Officer 89,419 $928.4K 2024-05-28 Merrill Lynch — EDGAR
2024-03-11 Mauro Anthony Officer 250,000 $3.08M 2024-03-11 PNC Investments — EDGAR
2024-03-05 Campbell Paul Officer 24,353 $300.3K 2024-03-05 Merrill Lynch — EDGAR
2024-03-05 Lyons Dillon JoEllen Director 20,000 $247.2K 2024-03-05 MERRILL LYNCH 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results · Other events EDGAR
2026-10-08 Material agreement · Other events EDGAR
2026-08-06 Earnings results · Other events EDGAR
2026-07-01 Material agreement · New debt obligation EDGAR
2026-06-18 Material agreement · New debt obligation EDGAR
2026-06-15 Other events EDGAR
2026-05-15 Shareholder vote results EDGAR
2026-05-07 Earnings results · Other events EDGAR
2026-05-04 Director or officer change · Regulation FD disclosure EDGAR
2026-02-26 Earnings results · Restructuring costs · Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-26 0001792044-26-000013 EDGAR
2025-02-27 0001792044-25-000008 EDGAR
2024-02-28 0001792044-24-000008 EDGAR
2023-02-27 0001792044-23-000008 EDGAR
2022-02-28 0001792044-22-000010 EDGAR
2021-03-01 0001792044-21-000009 EDGAR
2020-05-07 0001193125-20-136001 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001792044-26-000057 EDGAR
2026-08-06 0001792044-26-000041 EDGAR
2026-05-07 0001792044-26-000029 EDGAR
2025-11-06 0001792044-25-000046 EDGAR
2025-08-07 0001792044-25-000033 EDGAR
2025-05-08 0001792044-25-000018 EDGAR
2024-11-07 0001792044-24-000033 EDGAR
2024-08-08 0001792044-24-000025 EDGAR
2024-05-09 0001792044-24-000017 EDGAR
2023-11-08 0001792044-23-000033 EDGAR
ETF Holders
257 ETFs hold VTRS
25 shown · $3.90B total exposure · 0.06% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.03% $646.4M — 2026-09-30
2 VOO Vanguard S&P 500 ETF Vanguard 0.03% $534.5M — 2026-09-30
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.26% $458.1M — 2026-09-30
4 IVV iShares Core S&P 500 ETF iShares (BlackRock) 0.04% $307.4M $852.9B 2026-11-06
5 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.46% $298.2M — 2026-09-30
6 SPY State Street® SPDR® S&P 500® ETF Trust SPDR (State Street) 0.03% $267.2M $777.7B 2026-11-05
7 RSP Invesco S&P 500 Equal Weight ETF Invesco 0.23% $231.3M — 2026-11-05
8 XLV State Street® Health Care Select Sector SPDR® ETF SPDR (State Street) 0.32% $162.2M $49.9B 2026-11-05
9 COWZ Pacer US Cash Cows 100 ETF Nport 0.54% $101.4M — 2026-07-31
10 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.17% $99.0M $56.9B 2026-11-06
11 VYM Vanguard High Dividend Yield ETF Vanguard 0.09% $83.8M — 2026-09-30
12 IHE iShares U.S. Pharmaceuticals ETF iShares (BlackRock) 4.83% $77.7M $1.7B 2026-11-06
13 DUSA Davis Select U.S. Equity ETF Nport 5.37% $68.2M — 2026-07-31
14 VHT Vanguard Health Care ETF Vanguard 0.29% $63.1M — 2026-09-30
15 SPYM State Street® SPDR® Portfolio S&P 500® ETF SPDR (State Street) 0.03% $61.0M $177.9B 2026-11-05
16 SCHM Schwab U.S. Mid-Cap ETF Nport 0.36% $53.2M — 2026-08-31
17 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.06% $52.0M — 2026-11-05
18 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.06% $51.1M $82.9B 2026-11-06
19 DON WisdomTree U.S. Midcap Dividend Fund Nport 1.28% $50.8M — 2026-06-30
20 FTXH First Trust Nasdaq Pharmaceuticals ETF First Trust 4.12% $48.6M $1.2B 2026-11-06
21 WTV WisdomTree U.S. Value Fund Nport 1.40% $41.3M — 2026-06-30
22 IVE iShares S&P 500 Value ETF iShares (BlackRock) 0.08% $38.8M $50.4B 2026-11-06
23 FNDX Schwab Fundamental U.S. Large Company ETF Nport 0.14% $37.8M — 2026-08-31
24 SPMO Invesco S&P 500 Momentum ETF Invesco 0.20% $37.7M — 2026-11-05
25 IWS iShares Russell Mid-Cap Value ETF iShares (BlackRock) 0.23% $33.3M $14.8B 2026-11-06
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.52
TTM Revenue
$14.73B
TTM Net Income
$-607.80M
TTM Op. Cash Flow
$2.49B
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$3.75B$-325.30M$-0.28$899.40M
Q1 '262026-03-31$3.52B$176.40M$0.15$388.30M
Q4 '252025-12-31$3.70B$-340.10M$-0.30$815.80M
Q3 '252025-09-30$3.76B$-128.20M$-0.11$744.90M
Q2 '252025-06-30$3.58B$-4.60M—$219.70M
Q1 '252025-03-31$3.25B$-3.04B$-2.55$535.50M
Q4 '242024-12-31$3.53B$-516.50M$-0.43$482.70M
Q3 '242024-09-30$3.75B$94.80M$0.08$826.50M
Q2 '242024-06-30$3.80B$-326.40M$-0.27$379.10M
Q1 '242024-03-31$3.66B$113.90M$0.09$614.60M
Q4 '232023-12-31$3.84B$-765.60M$-0.63$568.50M
Q3 '232023-09-30$3.94B$331.60M$0.27$835.20M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.64
P/S
1.65
EV/EBITDA
11.52
EV/Sales
2.38
ROE
-2.0%
ROA
-0.8%
Div Yield
0.00%
FCF Yield
9.03%
Debt/Equity
0.85
Current Ratio
—
Market Cap
$24.03B
as of 2026-11-09

VTRS vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 46.0 +45.5% +31.3% 27
JNJ Johnson & Johnson $664.9B 42.9 +7.8% +36.2% 58
ABBV ABBVIE INC. $514.9B 50.6 +10.7% +28.1% 34
MRK Merck & Co., Inc. $361.7B 153.3 +4.9% +39.7% 45
AMGN Amgen Inc $249.0B 27.0 +8.2% +42.0% 34
GILD Gilead Sciences Inc $207.0B — +6.5% +39.5% 56
PFE Pfizer Inc. $167.5B 42.2 +1.3% +17.2% 58
BMY Bristol-Myers Squibb Co. $127.0B 13.8 +3.1% +17.1% 38
VTRS Viatris Inc. Common Stock $22.8B — +4.3% +64.5% 43
Peer median $305.4B 42.9 +7.2% +33.7% 42

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
37.93M
SI % of Float
3.31%
Days to Cover
4.57
Short Vol Ratio
64.5%
Free Float
1.15B
Float %
99.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-07